----item----
version: 1
id: {53238182-8C2F-4155-BC1B-02AC620A3D9E}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/05/15/Myriad Genetics links up with Ciba Pharmaceuticals US
parent: {166B4D89-6B6A-4D16-8DA9-761C7F941ECD}
name: Myriad Genetics links up with Ciba Pharmaceuticals US
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 36013497-4f76-4ac3-8115-b805db712aa5

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 524

<p>Myriad Genetics will retain worldwide diagnostic rights to cardiovascular genes discovered through a collaborative agreement with Ciba Pharmaceuticals (US). The $60 million, five-year agreement signed this month provides for $32 million in equity and research funding, a potential $28 million in milestone payments and future royalties. The collaboration will combine Myriad's gene technology and Ciba's pharmaceutical expertise. Ciba will receive an exclusive worldwide licence to all resulting therapeutic products.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 55

Myriad Genetics links up with Ciba Pharmaceuticals (US)
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1262

<p>Myriad Genetics will retain worldwide diagnostic rights to cardiovascular genes discovered through a collaborative agreement with Ciba Pharmaceuticals (US). The $60 million, five-year agreement signed this month provides for $32 million in equity and research funding, a potential $28 million in milestone payments and future royalties. The collaboration will combine Myriad's gene technology and Ciba's pharmaceutical expertise. Ciba will receive an exclusive worldwide licence to all resulting therapeutic products.</p><p>Myriad's gene discovery strategy involves two complementary technologies: genetic analysis of large families carried out in conjunction with the University of Utah; and gene mapping, isolation and DNA sequencing technologies. Using this approach, genetic discoveries in the past year have included the BRCA1 breast and ovarian cancer gene (see Clinica No 642, p 19), the tumour suppressor function of MTS1 and the localisation of the hereditary breast cancer gene, BRCA2 (see Clinica No 621, p 17).</p><p>"This agreement will allow us to accelerate our efforts to identify genes that put people at risk for cardiovascular disease and to move these discoveries into the marketplace," says Peter Meldrum, president and CEO of Myriad.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 53

Myriad Genetics links up with Ciba Pharmaceuticals US
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950515T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950515T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950515T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052643
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 55

Myriad Genetics links up with Ciba Pharmaceuticals (US)
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254452
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184238Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

36013497-4f76-4ac3-8115-b805db712aa5
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184238Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
